Colgate-Palmolive Company

🇺🇸New York Stock Exchange
Back to all articles
Colgate-Palmolive Company stock analysis CL overview
Bullish +75

Prediction: Colgate-Palmolive Will Jump 20% This Year

📈 Analysts project Colgate-Palmolive shares to gain 17.99% in the next 12 months, with a price target of $103.17 compared to current levels around $87.44.

🛡️ Investors view the stock as defensive due to its low beta (0.3), 63-year dividend streak, and resilient brand portfolio during economic downturns.

📊 Q1 2026 earnings beat analyst estimates with adjusted EPS of $0.97 versus consensus of $0.9445, extending a streak of four consecutive quarters of positive surprises.

🌍 Revenue growth was driven by international markets, with Latin America up 14.8% and Europe up 11.9%, partially offsetting a -1.8% decline in North American revenue.

💰 Free cash flow surged 27.94% to $609 million in Q1, while operating cash flow increased 24.5%, highlighting strong underlying liquidity generation.

📈 Organic sales growth is accelerating significantly from 0.4% in Q3 2025 to 2.9% in Q1 2026, with emerging markets specifically up 6.2%.

💵 The company raised its quarterly dividend to $0.53, marking the 63rd consecutive annual increase for shareholders.

🔧 SGPP restructuring aims to deliver $200-$300 million in annual pretax savings to fund advertising and recover margins once tariff pressures ease.

⚠️ Tariffs remain a key headwind, causing management to revise 2026 GAAP gross margin guidance downward due to the evolving geopolitical landscape.

📉 North America organic sales declined 2.2% in Q1, reflecting ongoing challenges in the domestic market despite global strength.

💸 A $919 million goodwill impairment related to the Filorga skin health business occurred in Q4 2025 due to weakness in the Chinese market.

📉 Current valuation reflects the goodwill charge with a trailing P/E of 34, though forward P/E drops to a more reasonable 23x.

🐻 Even in a bear-case scenario accounting for risks like tariff escalation, the projected downside is limited by the stock's low-beta and dividend yield.

🚀 Our bull-case scenario projects a total return of 22.99%, reaching a price target of $107.54 if current growth and margin trajectories hold.

🎯 Wall Street consensus includes 13 buy or strong buy ratings against zero sells, with an average price target of $96.00.

🤖 Long-term success depends on executing the 2030 strategy and reaching the high end of savings guidance from the SGPP program.

⚡ The setup favors low-volatility compounding growth for investors seeking stability in a murky macroeconomic environment.

🧨 Key risks to monitor include further tariff escalations beyond consumer staples and continued deterioration in North America volumes.

Bullish Signals
  • Our 24/7 Wall St. price target for Colgate-Palmolive is $103.17 over the next 12 months, implying 17.99% upside from current levels.
  • We rate the stock a buy with 90% confidence based on its strong defensive characteristics.
  • The stock has gained momentum with shares up 12.04% year to date and 4.33% over the past month, recovering from previous lows.
  • Q1 2026 adjusted earnings of $0.97 beat consensus estimates of $0.9445, extending a beat streak to four straight quarters.
  • Revenue grew 8.4% year-over-year to $5.324 billion, with Latin America surging 14.8% and Europe up 11.9%.
  • Free cash flow jumped significantly by 27.94% to $609 million in the first quarter.
  • Organic sales growth is accelerating from 0.4% in Q3 2025 to 2.9% in Q1 2026, with emerging markets up 6.2%.
  • The company's SGPP restructuring program targets $200-$300 million in annual pretax savings to fund growth initiatives.
  • Colgate maintains a robust dividend streak of 63 consecutive annual increases, with the most recent step-up to $0.53 per quarter.
  • Wall Street consensus includes 13 buy or strong buy ratings and zero sells, highlighting broad analyst support.
  • The forward P/E of 23 is viewed as more attractive than the trailing multiple due to one-time charges from goodwill impairments.
  • Operating cash flow grew 24.5% in Q1, demonstrating underlying financial strength despite macro headwinds.
Risk Factors
  • Management revised 2026 GAAP gross margin guidance from up to down due to the evolving tariff environment.
  • North America organic sales declined -1.8% in Q1, with a broader bear-case scenario indicating a -2.2% decline for the period.
  • Colgate recorded a $919 million goodwill impairment in Q4 2025 associated with weakness in its China market.
  • A trailing P/E of 34 leaves little room for execution slippage, exposing the stock to significant downside risk.
  • Key risks include potential tariff escalation broadening beyond consumer staples and further deterioration in North America volumes.
Full Analysis
Colgate-Palmolive (NYSE:CL) is highlighted as a defensive stock that performs well regardless of economic conditions, with investors drawn to its 63-year consecutive dividend streak and low beta profile. The article from Our 24/7 Wall St. provides a price prediction target of $103.17 for the next 12 months, suggesting approximately 18% upside from the current share price of $87.44, with a buy rating assigned at 90% confidence. Recent performance data shows the stock up 12.04% year to date as of early 2026, having recovered significantly from an October 2025 low of $77.63 and trading about 3% below its 52-week high of $98.72. Fundamental strength was reinforced during the May 1 Q1 2026 earnings report, where adjusted earnings per share of $0.97 beat consensus estimates of $0.9445 for the fourth consecutive quarter. Revenue reached $5.324 billion, representing an 8.4% year-over-year increase driven by Latin America (up 14.8%) and Europe (up 11.9%), though North America saw a slight decline of -1.8%. Free cash flow jumped to $609 million, a 27.94% increase, while the quarterly dividend increased to $0.53 per share, marking the 63rd consecutive annual hike. The bullish case relies on three primary pillars: accelerating organic sales growth, which improved from 0.4% in Q3 2025 to 2.9% in Q1 2026; an expanded SGPP restructuring program aimed at generating $200-$300 million in annual pretax savings to fund advertising and offset margin pressures; and the consistent dividend growth history. Analyst consensus estimates a price of $96.00 with predominantly buy ratings, while the article's bull-case scenario projects a total return up to 22.99%. Conversely, risks include ongoing tariff headwinds that forced management to revise its gross margin guidance downward and a specific impairment charge of $919 million recorded in Q4 2025 related to weakness in the Chinese skin-health business (Filorga). The company trades at a trailing P/E of 34 but a forward P/E of 23, with operating cash flow growing 24.5% in Q1. Even under bear-case assumptions, the stock is projected to reach $92.10, maintaining a floor that emphasizes downside protection provided by its beta of approximately 0.3 against broader market volatility.